Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0653 | 0.0865 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0653 | 0.0865 | 1 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0653 | 0.0865 | 0.0865 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.219 | 1 | 1 |
Toxoplasma gondii | PAN domain-containing protein | 0.1312 | 0.478 | 1 |
Brugia malayi | Trypsin family protein | 0.0653 | 0.0865 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.219 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0507 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0653 | 0.0865 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.219 | 1 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.219 | 1 | 1 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.0507 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0507 | 0 | 0.5 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.0507 | 0 | 0.5 |
Toxoplasma gondii | PAN domain-containing protein | 0.1312 | 0.478 | 1 |
Onchocerca volvulus | 0.0518 | 0.0066 | 0.0761 | |
Echinococcus granulosus | p2X purinoceptor 4 | 0.219 | 1 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.219 | 1 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.219 | 1 | 1 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0653 | 0.0865 | 0.0865 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.219 | 1 | 1 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.219 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.